Torrent Pharma's bid for Zentiva could be a step too far

Torrent Pharma seeks to boost its European footprint with the largest outbound transaction in India's pharmaceutical history. But it may not pay off for its shareholders.

Torrent Pharma's bid for Zentiva could be a step too far

On the face of it, Torrent Pharmaceutical's $2.5 billion bid for Sanofi's generic drug subsidiary Zentiva looks like a great deal for India’s 11th largest pharma firm by market cap. Similar product portfolios, new market penetration in 50 countries home to a billion people and an established pharma player in Eastern Europe all points to a sure winner for Torrent.

Zentiva is Europe’s third largest generic pharma company based...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

EVENTS